Who is sponsoring NCT05743023?

NCT05743023 is sponsored by Robert Schneider, MD.

What drugs are being tested in NCT05743023?

Interventions in NCT05743023: Ayurvedic lifestyle protocol.

What condition does NCT05743023 study?

NCT05743023 studies Breast Cancer Survivors.

Is NCT05743023 still recruiting?

NCT05743023 is currently status unknown. Last updated 24 February 2023.

Last reviewed 2023-02-24 · How we verify

NCT05743023

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Consciousness-based Ayurveda Lifestyle Program for Improving Quality of Life in Survivors of Breast Cancer

Status unknown NA Last updated 24 February 2023

What this trial tests

NA trial testing Ayurvedic lifestyle protocol in Breast Cancer Survivors in 15 participants. Status unknown.

Timeline

1 September 2022

Primary endpoint
1 April 2023

1 June 2023

Quick facts

Lead sponsor	Robert Schneider, MD
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	15
Start date	1 September 2022
Primary completion	1 April 2023
Estimated completion	1 June 2023
Sites	1 location across United States

Drugs / interventions tested

Ayurvedic lifestyle protocol

Conditions studied

Breast Cancer Survivors — all drugs for Breast Cancer Survivors →

Sponsor

Robert Schneider, MD

Who can join

18 and older, female only, with Breast Cancer Survivors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a pilot study to assess the feasibility and effectiveness of a 12-week intervention of personalized diet and lifestyle protocol based on the principles of Ayurveda's whole systems approach to achieving improvement in a) quality of life, b) digestive health, c) sleep among women breast cancer survivors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer Survivors

Currently open trials in the same condition.

NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07334626 — Impact of Pilates Exercises on Bone Mineral Density in Breast Cancer Survivors Receiving Hormonal Therapy · NA · recruiting
NCT07280143 — The Development of MASLD Among Survivors of Breast or Colorectal Cancer · recruiting
NCT07214883 — UCF MammoChat: Image Repository · recruiting
NCT07284030 — Psychoeducation and Well-Being After Breast Cancer · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05743023 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Robert Schneider, MD
Last refreshed: 24 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05743023.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing